Fatal Tumor Lysis Syndrome Following Sorafenib Treatment

George Habib, Munir Nashashibi


Sorafenib is one of the few approved treatments for advanced hepatocellar carcinoma. It is an oral multi-targeted tyrosine kinase inhibitor. It could be associated with a wide variety of adverse effects. However tumor lysis syndrome was reported in 2 cases only following sorafenib treatment. Here we report a fatal case of tumor lysis syndrome 3 weeks following sorafenib treatment in a patient with advanced hepatitis B virus-related hepatocellular carcinoma. We suggest using preventing measures for TLS prior to initiation of such treatment.

J Med Cases. 2013;4(4):269-270
doi: https://doi.org/10.4021/jmc1049w


Sorafenib; Tumor lysis syndrome; Hepatocellular carcinoma

Full Text: HTML PDF

Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics


World Journal of Oncology

Gastroenterology Research

Journal of Hematology


Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity


Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research


Journal of Neurology Research

International Journal of Clinical Pediatrics



Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.journalmc.org   editorial contact: editor@journalmc.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.